Photo from academic.microsoft.com
Immunogenomic analysis of advanced prostate cancer has identified immunological alterations associated with defective mismatch repair (dMMR) that could inform immunotherapy strategies. Overall, dMMR status was confirmed in 8.1% of patients… Click to show full abstract
Immunogenomic analysis of advanced prostate cancer has identified immunological alterations associated with defective mismatch repair (dMMR) that could inform immunotherapy strategies. Overall, dMMR status was confirmed in 8.1% of patients and was associated with poor overall survival; dMMR tumours with high microsatellite instability (MSI) had increased mutational load, T cell infiltration, and PDL1 expression. Interestingly, dMMR mutational signatures positively correlated with MSI and expression of immuneassociated genes, including PDL1 and PDL2.
Journal Title: Nature Reviews Urology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!